Becton, Dickinson & Company appoints new Managing Director for India & South Asia

New Delhi: BD (Becton, Dickinson and Company), a leading global medical technology company has appointed Pavan Mocherla as the new Managing Director for its India and South Asia operations. The medical technology giant aims to improve medical discovery, diagnostics and the delivery of care.

Mr Pavan will be relocating to India from the US to be at the helm of affairs in the country. With more than 25 years of experience across various industries, Pavan has held multiple positions and managed several projects in both emerging and developed markets. A strong believer in living the BD values of continuously improving and innovating and doing it right, he has been with BD for 14+years in business and strategic roles.

In his last assignment in BD for Strategic Innovation, he was instrumental in setting up an Innovation System to accelerate growth opportunities for the markets of China and South East Asia. In his current role, Pavan will be driving patient safety initiatives like Antimicrobial Resistance (AMR), Healthcare associated infections (HAI) reduction etc. and spearhead projects to improve access to technology in the global health space (HIV, TB etc.) through engagement with stakeholders across Government and multilateral agencies.

Prior to BD, he was associated with organisations like Whirlpool, ONIDA and NIIT Ltd. Pavan completed his MBA in Marketing from Central University, Pondicherry and Bachelors in Science from Osmania University, Hyderabad.

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For details, please visit bd.com

  • Related Posts

    Lilly launches Mounjaro KwikPen in India

    Mumbai, August 14, 2025 — Eli Lilly and Company (India) has rolled out the Mounjaro (tirzepatide) KwikPen across the country, expanding treatment choices for people with type-2 diabetes and those…

    Fortis Q1 Profit Jumps 57%; Expansion Drives Growth

      Gurugram, August 7 – http://Fortis HealthcareFortis Healthcare has reported a 57% year-on-year increase in its net profit for the first quarter of FY2025. The hospital chain posted ₹260 crore…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    4yo snakebite victim given anti-rabies shot at Sambhal hosp; pharmacist removed from duty

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Delhi High Court sets aside FSSAI order asking Red Bull India to drop ‘energy’ from its drinks

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Haryana to use Ayushman, Chirayu claim money for hospital staff incentives and upgrades: CM

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Indian speciality drugs get zero duty as US widens 100% tariff on patented medicines

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Low-dose CT screening lowers lung cancer deaths by 16% in high-risk people: IARC

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore

    Krsnaa Diagnostics board clears sale of diagnostic equipment worth up to Rs 120 crore